Barry, OppHub America Desk · · Source: yahoo-tickers-tape-movers
Assessment of the Pulmonary Arterial Hypertension (PAH) Market 2026-2036 Featuring United
Based on reporting from yahoo-tickers-tape-movers.
08, 2026 (GLOBE NEWSWIRE) -- The "Pulmonary Arterial Hypertension - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering. The pulmonary arterial hypertension (PAH) market across the United States, EU4 countries-Germany, France, Italy, and Spain-the United Kingdom
Shares a vertical MP4 loop to your phone's camera roll or app share sheet (Instagram, TikTok, Facebook Reels).
08, 2026 (GLOBE NEWSWIRE) -- The "Pulmonary Arterial Hypertension - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering. The pulmonary arterial hypertension (PAH) market across the United States, EU4 countries-Germany, France, Italy, and Spain-the United Kingdom, and Japan reached approximately USD 8 billion in 2025. The market is projected to expand at a compound annual growth rate of 6.7% from 2022 to 2036, supported by ri Assessment of the Pulmonary Arterial Hypertension (PAH) Market 2026-2036 Featuring United Therapeutics, Mochida Pharmaceutical, Johnson & Johnson, Merck, and Gossamer Bio
Read the full story
Original reporting and related coverage — attribution links only, not paid recommendations.
Trade this story
Robinhood
Webull
Tradier
IBKR
Chart this story
TradingView
Broker and exchange buttons use invite / refer-a-friend links (rewards may be capped). Charting links (TradingView) are partner offers that may pay OppHub America a commission at no extra cost to you.
OppSHOP
Full OppSHOP →As an Amazon Associate, OppHub America earns from qualifying purchases. Shopping here helps keep the site free — at no extra cost to you. Disclosure
OppSHOP
Related to this story
Assessment Pulmonary Arterial Hypertension PAH Market
Shop related →
Investing books
Read the classics
Shop this pick →
Personal finance books
Run the household books
Shop this pick →
Trading notebooks
Write the thesis first
Shop this pick →
Monitor for charts
See every pane
Shop this pick →
Story playbook
A pre-built map of what to watch — stocks, ETFs, and educational next steps. Not personalized advice.
Snapshot date: September 8, 2026 at 6:22 AM ET
This playbook was built when the story published and is not live-updated. Prices, news, and risk can change after this date — treat it as a starting map, not a current trade ticket.
Story → money map
Biotech & Specialty Pharma
A new research report highlights steady financial growth for the specialized medical market that treats severe lung and heart blood pressure conditions. Investors pay attention to this because major drug companies compete to capture a share of this growing multi-billion-dollar healthcare market.
What changed
Publication of a long-term market forecast and epidemiological report detailing growth projections for pulmonary arterial hypertension treatments through 2036.
Who wins / who loses
Established pharmaceutical companies with approved specialized therapies benefit from steady market expansion, while smaller developers face high clinical trial risks.
Time horizon
Think in terms of the next few months.
Confidence & best fit
medium confidence · Long-term investor
Safer theme exposure (ETFs)
Baskets that own the theme without betting on one company.
Single stocks (higher risk)
Primary = closest to the story · Peers = same industry · Second-order = knock-on effects · Avoid = looks related but may be a trap
Primary
- $UTHRWatch — track, don’t rush
A major healthcare company that focuses specifically on treating this exact lung condition.
View $UTHR chart → · End-of-day delayed data
Peer
- $JNJWatch — track, don’t rush
A massive healthcare company that makes these types of specialty medicines as part of its huge business.
View $JNJ chart → · End-of-day delayed data
- $MRKWatch — track, don’t rush
A giant drug company that invests heavily in developing treatments for serious medical conditions.
View $MRK chart → · End-of-day delayed data
Second-order
- $GOSSWatch — track, don’t rush
A smaller biotechnology company working on experimental treatments related to this medical market.
View $GOSS chart → · End-of-day delayed data
Options (education only)
No strikes or expiries — a framework for how traders might express the view. Options can expire worthless.
Beginners should skip options for this story, as industry reports rarely trigger immediate price moves.
See options-friendly brokers →Income / OppHub America angle
Not a trade tip — ways to use the insight outside the market.
- Research clinical trial pipelines for specialized pulmonary therapies in specialized medical journals.
What would break this thesis
- Regulatory setbacks or unfavorable clinical trial results for key pipeline treatments.
What to do next on OppHub America
Saved playbooks stay on this device for now.
Important
Not financial advice. OppHub America playbooks are educational market maps only — not recommendations to buy, sell, or hold any security. Markets move fast; information can be wrong or outdated. Trade and invest at your own risk. Do your own research or consult a licensed advisor.
Based on reporting from yahoo-tickers-tape-movers.
Informational and educational only — not investment, financial, or legal advice. Disclosure
Shares a vertical MP4 loop to your phone's camera roll or app share sheet (Instagram, TikTok, Facebook Reels).